Adverse events · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in adverse events compared with higher doses (low certainty).
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine may leads to lower laxation response: risk of spontaneous rescue‐free bowel movements… compared with higher doses (low certainty).
1 finding from 1 review
Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (dichotomous) · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes clinical improvement at 4 weeks (dichotomous) compared with oral prednisone (very low certainty).
1 finding from 1 review
Clinical improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement at 4 weeks (dichotomous) · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes histological improvement at 4 weeks (dichotomous) compared with oral prednisone (very low certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE pediatric patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes endoscopic improvement at 4 weeks (dichotomous) compared with oral prednisone (very low certainty).
1 finding from 1 review
Endoscopic improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether swallowed fluticasone changes withdrawals due to adverse events at 4 weeks compared with oral prednisone (very low certainty).
1 finding from 1 review
Gestational diabetes · pregnant women
Low‐GI dietary advice showed no clear difference in gestational diabetes compared with moderate‐ to high‐GI dietary advice (maternal outcomes) (low certainty).
1 finding from 1 review
Hypertensive disorders of pregnancy · pregnant women
1 finding from 1 review
Caesarean section · pregnant women
It is very uncertain whether low‐GI dietary advice changes caesarean birth compared with moderate‐ to high‐GI dietary advice (maternal outcomes) (very low certainty).
1 finding from 1 review
Perineal trauma · pregnant women
1 finding from 1 review
Gestational weight gain · pregnant women
It is very uncertain whether low‐GI dietary advice changes gestational weight gain (kg) compared with moderate‐ to high‐GI dietary advice (maternal outcomes) (very low certainty).
1 finding from 1 review
Postnatal depression · pregnant women
1 finding from 1 review
Type 2 diabetes mellitus · pregnant women
1 finding from 1 review
Perinatal mortality · pregnant women
1 finding from 1 review
Large‐for‐gestational age · pregnant women
It is very uncertain whether low‐GI dietary advice changes large‐for‐gestational age compared with moderate‐ to high‐GI dietary advice (child outcomes) (very low certainty).
1 finding from 1 review